Biogen Inc vs Invesco DB Agriculture Fund — how do they compare? Biogen Inc trades at $203.9 (market cap $30.60B), while Invesco DB Agriculture Fund trades at $27.6. The key difference: Biogen Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| BIIB | DBA | |
|---|---|---|
Market Cap | $30.60B | — |
Sector | Health | — |
52-Week High | $216.63 | $28.73 |
52-Week Low | $128.93 | $25.44 |
Enterprise Value | $37.67B | — |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
DBA, the Invesco DB Agriculture Fund ETF, trades at $27.62, up 0.69% today, and has shown strong performance with a 5% gain over the past month, outperforming the S&P 500. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights agricultural commodity strength, with DBA consolidating near highs amid a bullish trend since 2020, supported by a 3.25% yield and diversified futures exposure.
The outlook for DBA remains positive due to favorable agricultural market conditions and geopolitical factors driving commodity prices. Key risks include sector volatility and management fees. Analyst sentiment is constructive, viewing the ETF as a play on rising agricultural demand, though investors should monitor commodity price fluctuations and global supply chain disruptions.
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →